Comparison of QTc data analysis methods recommended by the ich E14 guidance and exposure-response analysis: Case study of a thorough QT study of asenapine

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 1, 2011, Pages 75-80

  Chapel, S ^a,c   Hutmacher, M M ^a,c   Bockbrader, H ^a,d   De Greef, R ^b   Lalonde, R L ^a,d  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ANN ARBOR PHARMACOMETRICS GROUP   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; PLACEBO; QUETIAPINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FALSE POSITIVE RESULT; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIPSYCHOTIC AGENTS; ARRHYTHMIAS, CARDIAC; BIAS (EPIDEMIOLOGY); COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FALSE POSITIVE REACTIONS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MODELS, BIOLOGICAL; PHARMACOLOGY, CLINICAL; PRACTICE GUIDELINES AS TOPIC; SCHIZOPHRENIA; TOXICITY TESTS;

EID: 78650516508     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.220     Document Type: Article

References (9)

1. US Food and Drug administration. International Conference on Harmonisation; Guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs; availability. Notice. Fed. Regist. 70, 61134-61135 (2005).
2. Darpo, B., Nebout, T. & Sager, P.T. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J. Clin. Pharmacol. 46, 498-507 (2006).
3. Chapel, S. et al. Exposure-response analysis in patients with schizophrenia to assess the efect of asenapine on QTc prolongation. J. Clin. Pharmacol. 49, 1297-1308 (2009).
4. Hutmacher, M.M., Chapel, S., Agin, M.A., Fleishaker, J.C. & Lalonde, R.L. Performance characteristics for some typical QT study designs under the ICH E-14 guidance. J. Clin. Pharmacol. 48, 215-224 (2008).
5. Russell, T., Riley, S.P., Cook, J.A. & Lalonde, R.L. A perspective on the use of concentration-QT modeling in drug development. J. Clin. Pharmacol. 48, 9-12 (2008).
6. Garnett, C.E. et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J. Clin. Pharmacol. 48, 13-18 (2008).
7. Wang, Y. & Garnett, C. Response to letter to the editor: Statistical issues of QT prolongation assessment based on linear concentration modeling by yi Tsong et al. J. Biopharm. Stat. 20, 689-692; author reply 693 (2010).
8. Patterson, S., Agin, M. & anziano, R. Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations: report from the Pharmaceutical Research and Manufacturers of america QT Statistics Expert Team. Drug Inf. J. 39, 243-265 (2005).
9. Saphris (asenapine sublingual tablets). Full prescribing information, Kenilworth, Nj: Schering-Plough, 2009.